Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ENTX vs MNOV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–5 Matrix Metrics)

ENTX Overall Winner 6-Pillar Tally: ENTX 3 – 2 MNOV (1 Tie) Matrix Metrics: ENTX 4 – 5 MNOV

As of Nov 20, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Medicinova, Inc. (MNOV) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 47.5/100 (HOLD) at $3.31 (N/M Forward P/E, 0.0% operating margin), whereas MNOV carries 50.2/100 (HOLD) at $1.31 (8.5x Forward P/E, -1232.2% operating margin).

  • Composite vs. Pillar Nuance: While MNOV currently prints a higher short-term Unified Composite Score (50.2/100 HOLD vs. ENTX 47.5/100 HOLD), ENTX captures the overall institutional head-to-head verdict (4–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1232.2% operating margin) and revenue trajectory (-100.0% vs. +12.4% YoY).
  • Technical & Structure Timing Caution: ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENTX vs MNOV
ENTX NASDAQ Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.31
+0.76% 1D
Market Cap $571.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 53% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 52.0 Fund 49.0 Flow 72.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 61
RSI-14: 61.2 · SMA20: $3.13 · SMA50: $2.93
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
TTM Revenue $935,717
Forward P/E 8.5x
Beta / 30D Vol 0.59β · 38% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.5%), weak momentum, RSI 36
RSI-14: 36.4 · SMA20: $1.40 · SMA50: $1.74

6-Pillar Scorecard Institutional Category Breakdown (ENTX 3 – 2 MNOV)

Columns: Metric · ENTX · MNOV
1. Valuation Multiples MNOV
Forward P/E N/M 8.5x
Trailing P/E N/M 8.5x
PEG Ratio N/M N/M
EV / Revenue N/M 42.5x
2. Growth & Scale MNOV
Revenue Growth (YoY) -100.0% +12.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $935,717
Market Cap $571.2M $65.1M
3. Profitability & Quality ENTX
Gross Margin N/A 42.2%
Operating Margin 0.0% -1232.2%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -20.3% -24.8%
4. Balance Sheet & Cash Flow ENTX
Cash Generation (TTM) -$16M -$9.1M
Cash Flow Margin N/A N/A
Net Cash / Leverage $265M Net Cash $25M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 116.0% (33rd %ile) 140.1% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENTX (4) vs MNOV (5)
Institutional Metric ENTX MNOV Criterion Row Edge
Market Capitalization
Scale
$571.2M $65.1M Larger Scale ENTX
Trailing P/E Ratio
Valuation
N/M 8.5x Lower Multiple MNOV
Forward P/E Ratio
Valuation
N/M 8.5x Lower Multiple MNOV
Revenue Growth (YoY)
Growth
-100.0% +12.4% Higher Growth MNOV
Operating Margin (TTM)
Profitability
0.0% -1232.2% Higher Margin ENTX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-20.3% -24.8% Higher ROE ENTX
52-Week Range Position
Momentum
73% ($1–$4) 3% ($1–$4) Stronger Trend ENTX
Beta / 30D Volatility
Risk Regime
0.92β · 53% Vol 0.59β · 38% Vol Lower Realized Risk MNOV
Unified Institutional Score
Composite Signal
47.5 / 100 (HOLD) 50.2 / 100 (HOLD) Higher Composite MNOV
Trailing 12M Revenue (USD)
Operating Scale
N/A $935,717 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 42.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 42.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$16M ($265M Net Cash) -$9.1M ($25M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENTX +16.53 pp
ENTX: +9.44% · MNOV: -7.09%
3M Horizon ENTX +11.02 pp
ENTX: -3.36% · MNOV: -14.38%
6M Horizon ENTX +172.96 pp
ENTX: +166.53% · MNOV: -6.43%
1Y Horizon ENTX +33.11 pp
ENTX: +24.72% · MNOV: -8.39%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ENTX Revenue MNOV Revenue ENTX Op. Margin MNOV Op. Margin Margin Leader
FY2012 N/A $0M N/A -1363.8% MNOV
FY2020 $0M N/A -3059.7% N/A ENTX
FY2021 $0M $0M -2139.6% -253.0% MNOV
FY2022 $0M N/A -9714.2% N/A ENTX
FY2023 N/A $0M N/A -990.0% MNOV
FY2024 $0M N/A -5295.6% N/A ENTX
FY2025 $0M $0M -27450.0% -3242.5% MNOV

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENTX CONSOLIDATION
83d in phase · OBV NEUTRAL
Current IV 116.0%
IV Percentile 33rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MNOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 140.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $571.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MNOV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $65.1M market capitalization and -1232.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENTX vs MNOV Key Questions & Quantitative Answers

As of Nov 20, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Medicinova, Inc. (MNOV) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 47.5/100 (HOLD) at $3.31 (N/M Forward P/E, 0.0% operating margin), whereas MNOV carries 50.2/100 (HOLD) at $1.31 (8.5x Forward P/E, -1232.2% operating margin). Composite vs. Pillar Nuance: While MNOV currently prints a higher short-term Unified Composite Score (50.2/100 HOLD vs. ENTX 47.5/100 HOLD), ENTX captures the overall institutional head-to-head verdict (4–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1232.2% operating margin) and revenue trajectory (-100.0% vs. +12.4% YoY). Technical & Structure Timing Caution: ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MNOV leads the Growth & Scale pillar: ENTX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MNOV at +12.4% YoY revenue growth and +0.0% YoY earnings growth on $935,717 TTM revenue (42.2% gross margin, -1232.2% operating margin). Across the 7-period historical trajectory (FY2012 to FY2025), ENTX cumulative revenue shifted N/A while MNOV shifted N/A. In operating R&D and SG&A reinvestment, ENTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MNOV.

MNOV screens cheaper on headline valuation multiples. ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MNOV trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 42.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTX (-20.3% ROE) versus MNOV (-24.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ENTX carries 116.0% implied volatility (33rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 53% Vol realized risk). By comparison, MNOV carries 140.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.